Clinicopathologic criteria were used to group 68 cats according to high, moderate, or low suspicion of having feline leukemia virus (FeLV)-related disease. Peripheral blood samples were tested for FeLV antigen by enzyme-linked immunosorbent assay (ELISA) and for FeLV DNA by polymerase chain reaction (PCR). There was no significant difference between ELISA and PCR results in the 68 cats. In the high-suspicion group, 46% (11/24) of cytopenic cats were test positive (ELISA and PCR) and 87% (13/15) with hemopoietic neoplasms were test-positive. Also within the high suspicion group, test-positive cats were 2.5 times more likely to die within the 1 year follow-up period than were test-negative (ELISA and PCR) cats. Among cats in the moderatesuspicion group, 15% (2/13) were test-positive, and none (0/16) of the cats in the low suspicion group was test positive. The relative risk of a positive test (ELISA and PCR) in the high suspicion group was 3.7 times that for the moderate-suspicion group and 22.8 times that for the low suspicion group. There was no significant difference in the relative risk of a positive test result between the moderate and low suspicion groups. The results indicate that FeLV detection by PCR can be adapted for diagnostic purposes using peripheral blood samples, however, results do not differ significantly from FeLV ELISA results. Also, a proportion of cats with a high suspicion of having FeLV-related cytopenia and hemopoietic tumors are negative for both circulating FeLV antigen and DNA. These cats may not have FeLV-related disease, or FeLV may exist in a diseaseproducing but nonreplicating form ultimately detectable by PCR in tissues other than peripheral blood.
Feline leukemia virus (FeLV) is a horizontally transmitted oncogenic, myelosuppressive, and immunosuppressive retrovirus and represents the most important pathogen of domestic cats. 8, 32 Both degenerative and neoplastic conditions of the hemopoietic system can be directly related to naturally occurring FeLV infection. 6, 7, 9, 32, 33 A proportion of cats have clinicopathologic findings consistent with FeLV infection but are FeLV negative using antigen detection tests that rely on viral replication. Circulating FeLV antigen is present in about 70% of cats with nonregenerative anemia, 88% with myeloproliferative disease (excluding lymphosarcoma), 70% with lymphosarcoma, and 80% with myelodegenerative disease. 2,7 However, there is evidence that incorporation of FeLV within the DNA of host cells without accompanying viral replication causes disease in some cats. 11, 15, 25, 34, 41 Also, high levels of unintegrated FeLV DNA have been associated with disease progression of the acquired immunodeficiency strain of FeLV. 28 Traditionally, FeLV infection has been diagnosed using the immunofluorescent antibody (IFA) test for cell-associated viral antigens, or the enzyme-linked immunosorbent assay (ELISA) which detects soluble FeLV group-specific antigens in the plasma or serum of FeLV-infected cats. 12 The polymerase chain reaction (PCR) facilitates the detection of minute amounts of DNA in tissues and is particularly useful in instances where infectious virus particles are nonreplicating or are present in very low numbers. 14, 39 The PCR has been successfully used to detect FeLV in fresh and formalin-fixed feline tissues 5, 15, 27 and can detect FeLV DNA in lymphoid tumors negative for antigen expression. 15 In this study FeLV was detected by PCR in peripheral blood samples collected from cats with clinicopathologic abnormalities and various levels of suspicion of having FeLV-related disease. These samples were submitted for routine testing to a diagnostic laboratory. The objective of the study was to investigate the prevalence of FeLV as detected by ELISA versus PCR to determine if some cats harbored FeLV DNA in peripheral blood cells without expressing viral antigen.
Materials and methods
Case selection. The study group comprised 68 cats presented to the Western College of Veterinary Medicine and private veterinary clinics with variable clinicopathologic evidence of FeLV infection. All available clinical, hematologic, biochemical, and necropsy information was used to group cats according to degree of suspicion of FeLV-related disease. The high suspicion group was subdivided into 2 groups. The first group included cats with peripheral cytopenia without evidence of hemopoietic neoplasia, defined as one or more of the following: severe nonregenerative anemia (packed cell volume [PCV] .
≤ 0.15 liters/liter; reference range, 0.24-0.45 liters/liter), severe neutropenia (neutrophil count ≤ 1.5 x 10 9 /liter; reference range, 2.5-12.5 x 10 9 /liter), and/or severe thrombocytopenia (platelet count ≤ 50 x 10 9 /liter; reference range, 300-500 x 10 9 /liter). The second group included cats with hemopoietic neoplasia involving erythrocytes, lymphocytes, granulocytes, monocytes, and/or thrombocytes. The moderate suspicion group included cats with diseases sometimes associated with FeLV, such as feline infectious peritonitis (FIP), hemobartonellosis accompanied by a regenerative anemia, and chronic, nonresponsive inflammatory conditions, as well as unexplained hematologic abnormalities exclusive of those in the high suspicion group. These abnormalities included red cell macrocytosis unaccompanied by anemia (mean corpuscular volume > 55 fl; reference range, 39-55 fl), circulating atypical lymphocytes, mild to moderate anemia (PCV = 0.16-0.23 liters/liter), and/or mild to moderate neutropenia (neutrophil count = 1.6-2.4 x 10 9 /liter). The low suspicion group included cats with diseases or conditions not generally associated with FeLV, such as chronic renal failure, feline urologic syndrome, pancreatitis, nonhemopoietic tumors, and primary fatty liver syndrome, or cats with vague illness and normal hematologic findings. The follow-up period was a minimum of 1 year from initial testing. The follow-up included a review of the clinical record, consultation with the attending clinician, and/or direct contact with the owner. Death was natural or by euthanasia and was classified as FeLV-related or FeLV-unrelated.
Laboratory data. The minimum data collected from each cat included a complete blood count (CBC), ELISA for FeLV antigen, and PCR for FeLV DNA. The CBCs were done using an electronic multichannel cell counting analyzer a and manual techniques as previously described. 16 The ELISAs to detect FeLV p27 antigen were done using 1 of 2 commercial test kits according to the manufacturers' instructions. b,c PCR. Template DNA for the PCR was extracted from peripheral blood samples collected into ethylenediaminetetraacetic acid vacuum tubes. The procedure for genomic DNA extraction has been previously described. 31 The buffy coat was separated from 0.25-2.0 ml of anticoagulated whole blood and transferred to a 1.5-ml microfuge tube. Then 1 ml of double distilled water was added, the sample was vortexed briefly, and 250 µl of 5 x standard saline citrate (SSC) was added and mixed. The lysate was microfuged for 3 min, the supernatant was removed, 1 ml of 1 x SSC was added, and the sample was vortexed briefly and spun for 2 min. The supernatant was removed, and the buffy coat was resuspended in 500 µl of 1 x SSC; 35 µl of 20% sodium dodecyl sulfate was added, and the sample was mixed and left at room temperature for 5 min. Then 12 µl of Proteinase K d (20 mg/ml) was added, and the sample was mixed and incubated at 65 C overnight. Following overnight digestion, samples were extracted once with phenol, twice with phenolchloroform-isoamyl alcohol (25:24:l) , and once with chlo-roform-isoamyl alcohol (24:1), and then precipitated with ethanol according to standard technique. 38 The dried samples were resuspended in 50 µl of high-performance liquid chromatography-grade water. e A 1-10-µl sample volume was used as template for the PCR.
The protocol for amplification of a 166 base pair segment of the FeLV long terminal repeat (LTR) has been previously described for application to formalin-fixed, paraffin-embedded feline lymphoid tumors. 15 No modifications were made for DNA template extracted from peripheral blood samples. Southern hybridization using a nonradiolabeled probe and positive and negative controls and sequencing of amplified products were as previously described. 15 Results from clinical cases were accepted and interpreted only when controls produced the expected result on agarose gel electrophoresis (AGE) of a 10-µl aliquot of PCR product. A definite band of the appropriate size (166 bp) on AGE was interpreted as positive for FeLV provirus; Southern hybridizations were done randomly on such samples to confirm specificity of the PCR for exogenous FeLV LTR. The PCR was repeated at least once on samples yielding negative or equivocal results. Samples were considered negative if no 166 bp band was visualized on AGE of PCR products from 2 PCRs. Samples with equivocal results on AGE were accepted as either positive or negative based on Southern hybridization findings. If both AGE and Southern hybridization results were equivocal, the sample was interpreted to be negative for FeLV provirus.
Statistical analysis. McNemar's chi-square test for 2 related samples 26 was used to compare the FeLV infection rate diagnosed by ELISA with that diagnosed by PCR. Within the high-suspicion group, the risk of death in test-positive cats was compared with the risk of death in test-negative cats by calculating relative risk and test-based 95% confidence intervals. 37 Cats with positive results by both ELISA and PCR were considered test positive, those with negative results by both ELISA and PCR were considered test negative, and the remainder were test discordant. Discordant results were excluded from the calculation of risk of death. For estimating risk, cats were considered to have survived if the clinical outcome was unknown.
The association between test result and disease suspicion category was examined using chi-square analysis. 3 If the overall relationship was significant among the 3 disease suspicion categories, the relationship between categories (high vs. moderate, high vs. low, and moderate vs. low) was examined. If any cell total was 0, then the quantity 0.5 was added to all cells for the calculations. Fisher's exact test was used when appropriate. 3 Table 1 shows the FeLV test results and clinical outcomes in 68 cats with high, moderate, or low suspicion of having FeLV-related disease. There was no significant difference between FeLV ELISA and PCR results (P = 0.5637). In the high suspicion group, 2 cats were weakly positive by ELISA (reported here as ELISA positive) but were unquestionably positive by PCR. Only 3 cats, all within the cytopenia subgroup, had discordant results. The 2 ELISA-positive/PCR-negative cats included 1 6-year-old cat with severe nonregenerative macrocytic anemia that died 8 months after diagnosis and a 1-year-old cat with severe neutropenia that was well 2 years after diagnosis. The 1 ELISA-negative/PCR-positive cat was 14 years old with chronic neutropenia and was well 2 years after testing. Twenty-five cats died out of the 39 (64%) in the high suspicion group, all as a result of FeLV-related disease. Within the high suspicion group, test-positive cats were 2.5 times more likely to die during the follow-up period than were test-negative cats (Fisher's exact, 2-tailed: P = 0.0067, test-based 95% confidence interval = 1.3-4 9)
Results
. . Of the 13 cats in the moderate suspicion group, 4 had hemobartonellosis, 3 had FIP, 2 had chronic nonresponsive inflammatory disease, and 4 had various hematologic abnormalities. One of 2 test-positive cats that died in the moderate suspicion group had hemobartonellosis, the other had chronic nonresponsive diarrhea. Three of the 6 test-negative cats that died in the moderate-suspicion group had FIP, 1 had intravascular hemolysis and pyothorax, 1 had chronic intestinal and respiratory infections with terminal disseminated intravascular coagulation, and 1 had erythrocyte macrocytosis but died 2 years later with diabetes mellitus. Two cats died in the low suspicion group, 1 with chronic renal failure and 1 with hemangiosarcoma.
Thirty-three of the 39 cats in the high suspicion group were 58 years old, 11 of the 13 in the moderate suspicion group were -≤8 years old, and 12 of the 16 in the low suspicion group were 58 years old. In the high suspicion group, the 2 test-negative cats with hemopoietic tumors were >8 years old and had lymphosarcoma without evidence of leukemia. Table 2 shows the likelihood of a positive test according to the pretest suspicion group. There were sig-nificant differences in positivity rates between the high and moderate suspicion groups (x 2 = 10.10, P = 0.001) and between the high and low suspicion groups (x 1 = 19.81, P < 0.0001). There was no significant difference in positivity rates between the moderate and low suspicion groups (Fisher's exact test: P = 0.19). Cats in the high suspicion diagnostic category were 3.7 times more likely to be test positive than were cats in the moderate suspicion diagnostic category (relative risk = 3.70, 95% confidence interval = 1.65-8.29). Similarly, cats in the high suspicion diagnostic category were about 23 times more likely to be test positive than were cats in the low suspicion category (relative risk = 22.80, 95% confidence interval = 5. 76-90.25) .
Discussion
In this study, 13 of 39 cats (33%) with high clinicopathologic suspicion of having FeLV-related disease were ELISA negative. Previous studies have also shown that only a proportion of cats with diseases often associated with FeLV are positive for circulating FeLV antigen. 2,7 If these antigen-negative cats have very low levels of infective virus or are infected with latent or defective forms of FeLV, then PCR might be expected to detect viral DNA in this group of cats. However, this study showed no difference between ELISA and PCR results in 68 cats grouped according to level of suspicion of FeLV-related disease.
The ELISA is a sensitive test for circulating FeLV antigen, requiring only 0.2 ml of serum, plasma, or anticoagulated whole blood and being unaffected by peripheral cytopenia. 13 The PCR technique allows detection of minute amounts of viral DNA in tissues. 14, 39 In this study, PCR was performed with peripheral blood that remained after all other diagnostic tests were completed; in many cases there was only 0.25 ml of blood, often with a very low nucleated cell count. Despite the potential limitations of sample quantity and quality, the FeLV detection rate was the same with PCR and the ELISA.
We examined peripheral blood so that PCR could be evaluated in direct relation to ELISA; however, cats harboring latent or defective virus may do so only in certain tissues such as bone marrow, lymph nodes, or epithelial tissues. 21, 25, 35 Antigen could be released from such sites periodically without cell-associated viremia, or antigen may never be released in the case of replication-defective but disease-producing FeLV. The high suspicion test-negative cats may have harbored FeLV in tissues other than peripheral blood cells, the target region for the PCR primers may have been unrecognizable due to mutation or deletion, sample limitations may have produced false-negative results, or the hematologic abnormalities in these cats may not have been FeLV related.
Virus isolation and IFA results usually correlate well, 10,22 whereas a proportion of cats are ELISA positive and IFA or virus isolation negative. 12, [18] [19] [20] 24 Controversy exists over whether ELISA positive/IFA negative cats are ELISA false positive, IFA false negative, in the primary stage of infection before development of cell-associated viremia, in a transient phase of infection before recovery, or experiencing latent infection with periodic low level antigenemia. We found no significant difference between ELISA and PCR results, implying that ELISA positive cats in this group also had cell-associated viral DNA and were probably true positives. Although the 3 discordant cats did not significantly affect the results and interpretation, possible explanations are false-positive or false-negative ELISA or PCR results, antigenemia without cell-associated viremia in the 2 ELISA positive/PCR negative cats, or defective or latent virus in peripheral blood cells with no or low level antigenemia in the ELISA negative/PCR positive cat. This third cat was 14 years old and had chronic neutropenia and few clinical signs.
The two test-negative cats with hemopoietic neoplasia (lymphosarcoma) were >8 years old and had solid tumors with no leukemia. In archival lymphosarcoma tissue from old cats, FeLV DNA can be detected by PCR more often than FeLV antigen can be detected by immunohistochemistry. 15 In the present study, direct examination of tumor tissue for proviral DNA may have revealed FeLV in the 2 cats with negative peripheral blood results.
The rate of a positive test among high suspicion cases was 66.7% but was only 6.9% among the combined moderate and low suspicion cases. The relative risk of being test positive was not significantly different between the moderate and low suspicion groups. The number of cats in the moderate suspicion group may have been too low to detect a difference, or a relationship between FeLV and conditions such as hemobartonellosis, FIP, and chronic inflammatory diseases may be overemphasized. Some reports suggest that FeLV is involved in 30.50% of hemobartonellosis cases, 40-60% of FIP cases, and 52-60% of chronic nonresponsive infections. 2, 7, 17, 36, 42 In a large retrospective study, only 19% of FIP cases were FeLV antigen positive, and several mycotic, viral, and parasitic infections had no significant association with FeLV infection. 32, 33 Results from our study support grouping cats by clinicopathologic findings according to only 2 levels of suspicion of FeLV-related disease.
Test-positive cats in the high suspicion group were 2.5 times more likely to die during the follow-up period than were test-negative cats in the same group. The relative risk of death for these test-positive cats may be understated. Cats with unknown clinical outcomes were considered to be alive for the purpose of the calculation, and all 4 cats with unknown outcomes were test positive. These 4 cats were very ill and in most cases were sent home to die, although at the time of follow-up, the owners could not be located.
Epidemiologic studies show that about 50% of viremic cats die within 6 months and 80-100% die within 3 years of FeLV diagnosis. 17, 29 In this study, 8 of 12 test-negative cats in the high suspicion group were alive at least 1 year following testing. The better prognosis in these test-negative cats may indicate they were not FeLV infected or that FeLV infection was transient and undetectable at the time of testing and recovery occurred. Whether test-positive cats were euthanized more readily than test-negative cats with the same clinicopathologic abnormalities is not known. However, the survival rate at 1 year suggests that test-negative cats in this group had a better prognosis, which is not explained solely by higher euthanasia rates in test-positive cats.
There are no previous reports comparing FeLV detection by ELISA and by PCR in sick cats; however, conflicting results appear in the literature comparing PCR to serology for human immunodeficiency virus (HIV) diagnosis in high-risk groups. 1, 4, 23, 30, 40 Some describe a high percentage of PCR-positive/antibodynegative patients, 23,40 whereas others have found no difference between PCR and serology results and suggest that antigen and antibody tests are appropriate and conclusive most of the time. 1, 4 Generally, serologic data, including HIV-1 antigen tests, agree with nucleic acid detection data. However, PCR is useful for evaluating infants born to seropositive mothers who have detectable HIV antibody that may persist for as long as 15 months, 30 patients prior to seroconversion, patients receiving anti-retroviral treatment, and patients with inconclusive serologic tests. 23, 30 Many of these situations do not exist in the case of FeLV. Traditional FeLV tests detect viral antigen, which appears early in infection and usually persists if an adequate immune response is not raised. 19, 35, 36 In this study, 2 samples were weakly positive by ELISA but unquestionably positive by PCR; PCR may be useful in such cases of uncertainty. Many clinicians accept weakly positive ELISA results as positive, as we did for this study, whereas others recommend retesting in the near future and/or IFA testing.
PCR has been used for retrospective FeLV detection in formalin-fixed, paraffin-embedded lymphoid tumors from cats. 15 With PCR, FeLV DNA was detected in tumors from a significant proportion of older cats (>7 years old) that were negative for viral antigen by immunohistochemistry. These results suggest that defective or latent virus may be involved in tumor development in a subgroup of older cats. We were unable to show a similar relationship in the present study using peripheral blood from cats with hematologic abnormalities often associated with FeLV. However, 33 of the 39 cats in the high suspicion group were young to middle aged (58 years old). Perhaps with PCR, only additional FeLV-positive older cats can be detected; these older cats may be more likely to have latent or defective FeLV. A molecular technique such as PCR is ideally suited to explore the question of latent or replication-defective FeLV infection. Tissues other than peripheral blood may have to be examined by PCR to support or refute a role for FeLV in the pathogenesis of antigen-negative but FeLV-suspect disease.
